Potentiation and Mechanism of Berberine as an Antibiotic Adjuvant Against Multidrug-Resistant Bacteria

References

• World Health Organization. Global antimicrobial resistance and use surveillance system (‎GLASS)‎ report: 2022; 2022. Available from: https://www.who.int/publications-detail-redirect/9789240062702. Accessed November 1, 2023.
   Google Scholar
• Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi:10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• O’Neill J Tackling drug-resistant infections globally: final report and recommendations. (Review on Antimicrobial Resistance, London). 2016. Available from: https://wellcomecollection.org/works/thvwsuba. Accessed November 1, 2023.
   Google Scholar
• Christaki E, Marcou M, Tofarides A. Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. J Mol Evol. 2020;88(1):26–40. doi:10.1007/s00239-019-09914-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed November 1, 2023.
   Google Scholar
• Douafer H, Andrieu V, Phanstiel O, Brunel JM. Antibiotic adjuvants: make antibiotics great again! J Med Chem. 2019;62(19):8665–8681. doi:10.1021/acs.jmedchem.8b01781
   PubMed Web of Science ®Google Scholar
• Liu Y, Li R, Xiao X, Wang Z. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria. Crit Rev Microbiol. 2019;45(3):301–314. doi:10.1080/1040841X.2019.1599813
   PubMed Web of Science ®Google Scholar
• Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020;14(5):564–582. doi:10.1007/s11684-019-0724-6
   PubMed Web of Science ®Google Scholar
• Kong Y, Li L, Zhao LG, Yu P, Li DD. A patent review of berberine and its derivatives with various pharmacological activities (2016–2020). Expert Opin Ther Pat. 2022;32(2):211–223. doi:10.1080/13543776.2021.1974001
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Xu Q, et al. Berberine and health outcomes: an umbrella review. Phytother Res. 2023;37(5):2051–2066. doi:10.1002/ptr.7806
   PubMed Web of Science ®Google Scholar
• Hobson C, Chan AN, Wright GD. The antibiotic resistome: a guide for the discovery of natural products as antimicrobial agents. Chem Rev. 2021;121(6):3464–3494. doi:10.1021/acs.chemrev.0c01214
   PubMed Web of Science ®Google Scholar
• Millar BC, Rao JR, Moore JE. Fighting antimicrobial resistance (AMR): Chinese herbal medicine as a source of novel antimicrobials – an update. Lett Appl Microbiol. 2021;73(4):400–407. doi:10.1111/lam.13534
   PubMed Web of Science ®Google Scholar
• Jadimurthy R, Mayegowda SB, Nayak SC, Mohan CD, Rangappa KS. Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds. Biotechnol Report. 2022;34:e00728. doi:10.1016/j.btre.2022.e00728
   Google Scholar
• Herman A, Herman AP. Herbal products and their active constituents used alone and in combination with antibiotics against multidrug-resistant bacteria. Planta Med. 2023;89(02):168–182. doi:10.1055/a-1890-5559
   PubMed Web of Science ®Google Scholar
• Feng X, Sureda A, Jafari S, et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics. 2019;9(7):1923–1951. doi:10.7150/thno.30787
   PubMed Web of Science ®Google Scholar
• Patel P. A bird’s eye view on a therapeutically ‘wonder molecule’: berberine. Phytomed Plus. 2021;1(3):100070. doi:10.1016/j.phyplu.2021.100070
   Google Scholar
• Chen C, Yu Z, Li Y, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract — a review of actions and therapeutic implications. Am J Chin Med. 2014;42(05):1053–1070. doi:10.1142/S0192415X14500669
   PubMedGoogle Scholar
• Zhang L, Wu X, Yang R, et al. Effects of berberine on the gastrointestinal microbiota. Front Cell Infect Microbiol. 2020;10:588517. doi:10.3389/fcimb.2020.588517
   PubMed Web of Science ®Google Scholar
• Chu M, Zhang MB, Liu YC, et al. Role of berberine in the treatment of methicillin-resistant staphylococcus aureus infections. Sci Rep. 2016;6(1):24748. doi:10.1038/srep24748
   PubMedGoogle Scholar
• Jamshaid F, Dai J, Yang LX. New development of novel berberine derivatives against bacteria. MRMC. 2020;20(8):716–724. doi:10.2174/1389557520666200103115124
   Google Scholar
• Ghareeb DA, Saleh SR, Seadawy MG, et al. Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity. J Pharm Investig. 2021;51(6):735–757. doi:10.1007/s40005-021-00544-w
   PubMed Web of Science ®Google Scholar
• Zhang C, Sheng J, Li G, et al. Effects of berberine and its derivatives on cancer: a systems pharmacology review. Front Pharmacol. 2019;10:1461. doi:10.3389/fphar.2019.01461
   PubMed Web of Science ®Google Scholar
• Devarajan N, Jayaraman S, Mahendra J, et al. Berberine—A potent chemosensitizer and chemoprotector to conventional cancer therapies. Phytother Res. 2021;35(6):3059–3077. doi:10.1002/ptr.7032
   PubMed Web of Science ®Google Scholar
• Ai X, Yu P, Peng L, et al. Berberine: a review of its pharmacokinetics properties and therapeutic potentials in diverse vascular diseases. Front Pharmacol. 2021;12:762654. doi:10.3389/fphar.2021.762654
   PubMed Web of Science ®Google Scholar
• Singh S, Pathak N, Fatima E, Negi AS. Plant isoquinoline alkaloids: advances in the chemistry and biology of berberine. Eur J Med Chem. 2021;226:113839. doi:10.1016/j.ejmech.2021.113839
   PubMed Web of Science ®Google Scholar
• Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33(3):504–523. doi:10.1002/ptr.6252
   PubMed Web of Science ®Google Scholar
• Khoshandam A, Imenshahidi M, Hosseinzadeh H, et al. Pharmacokinetic of berberine, the main constituent of Berberis vulgaris L: a comprehensive review. Drug Deliv and Transl Res. 2022;36(11):4063–4079. doi:10.1002/ptr.7589
   Google Scholar
• Xiong RG, Huang SY, Wu SX, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: an update review. Molecules. 2022;27(14):4523. doi:10.3390/molecules27144523
   PubMed Web of Science ®Google Scholar
• Coates ARM, Hu Y, Holt J, Yeh P. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther. 2020;18(1):5–15. doi:10.1080/14787210.2020.1705155
   PubMed Web of Science ®Google Scholar
• Liu Y, Tong Z, Shi J, Li R, Upton M, Wang Z. Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria. Theranostics. 2021;11(10):4910–4928. doi:10.7150/thno.56205
   PubMed Web of Science ®Google Scholar
• Norden CW, Wentzel H, Keleti E. Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis. 1979;140(4):629–633. doi:10.1093/infdis/140.4.629
   PubMed Web of Science ®Google Scholar
• Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol. 2016;24(11):862–871. doi:10.1016/j.tim.2016.06.009
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed; 2019. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed November 1, 2023.
   Google Scholar
• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
   PubMed Web of Science ®Google Scholar
• Koulenti D, Song A, Ellingboe A, et al. Infections by multidrug-resistant gram-negative bacteria: what’s new in our arsenal and what’s in the pipeline? Int J Antimicrob Agents. 2019;53(3):211–224. doi:10.1016/j.ijantimicag.2018.10.011
   PubMed Web of Science ®Google Scholar
• Song M, Liu Y, Huang X, et al. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens. Nat Microbiol. 2020;5(8):1040–1050. doi:10.1038/s41564-020-0723-z
   PubMed Web of Science ®Google Scholar
• Holger D, Kebriaei R, Morrisette T, Lev K, Alexander J, Rybak M. Clinical Pharmacology of Bacteriophage Therapy: a Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics. 2021;10(5):556. doi:10.3390/antibiotics10050556
   Google Scholar
• Sörensen M, Khakimov B, Nurjadi D, et al. Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients. Antimicrob Resist Infect Control. 2020;9(1):197. doi:10.1186/s13756-020-00859-7
   PubMed Web of Science ®Google Scholar
• Leroy AG, Caillon J, Caroff N, et al. Could azithromycin be part of Pseudomonas aeruginosa acute pneumonia treatment? Front Microbiol. 2021;12:642541. doi:10.3389/fmicb.2021.642541
   PubMedGoogle Scholar
• Li Y, Huang J, Li L, Liu L. Synergistic activity of berberine with azithromycin against Pseudomonas Aeruginosa isolated from patients with cystic fibrosis of lung in vitro and in vivo. Cell Physiol Biochem. 2017;42(4):1657–1669. doi:10.1159/000479411
   PubMedGoogle Scholar
• Morita Y, Nakashima KI, Nishino K, et al. Berberine is a novel type efflux inhibitor which attenuates the MexXY-mediated aminoglycoside resistance in pseudomonas aeruginosa. Front Microbiol. 2016;7:1223. doi:10.3389/fmicb.2016.01223
   PubMed Web of Science ®Google Scholar
• Laudadio E, Cedraro N, Mangiaterra G, et al. Natural alkaloid berberine activity against Pseudomonas aeruginosa MexXY-mediated aminoglycoside resistance: in silico and in vitro studies. J Nat Prod. 2019;82(7):1935–1944. doi:10.1021/acs.jnatprod.9b00317
   PubMed Web of Science ®Google Scholar
• Mangiaterra G, Cedraro N, Laudadio E, et al. The natural alkaloid berberine can reduce the number of Pseudomonas aeruginosa Tolerant cells. J Nat Prod. 2021;84(4):993–1001. doi:10.1021/acs.jnatprod.0c01151
   PubMed Web of Science ®Google Scholar
• Su F, Wang J. Berberine inhibits the MexXY‑OprM efflux pump to reverse imipenem resistance in a clinical carbapenem‑resistant Pseudomonas aeruginosa isolate in a planktonic state. Exp Ther Med. 2018;15(1):467–472. doi:10.3892/etm.2017.5431
   PubMed Web of Science ®Google Scholar
• Li X, Song Y, Wang L, et al. A potential combination therapy of berberine hydrochloride with antibiotics against multidrug-resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 2021;11:660431. doi:10.3389/fcimb.2021.660431
   PubMed Web of Science ®Google Scholar
• Shi C, Li M, Muhammad I, et al. Combination of berberine and ciprofloxacin reduces multi-resistant Salmonella strain biofilm formation by depressing mRNA expressions of luxS, rpoE, and ompR. J Vet Sci. 2018;19(6):808. doi:10.4142/jvs.2018.19.6.808
   PubMed Web of Science ®Google Scholar
• Zhou XY, Ye XG, He LT, et al. In vitro characterization and inhibition of the interaction between ciprofloxacin and berberine against multidrug-resistant Klebsiella pneumonia e. J Antibiot. 2016;69(10):741–746. doi:10.1038/ja.2016.15
   PubMed Web of Science ®Google Scholar
• Yu HH, Kim KJ, Cha JD, et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J Med Food. 2005;8(4):454–461. doi:10.1089/jmf.2005.8.454
   PubMed Web of Science ®Google Scholar
• Zuo GY, Li Y, Han J, Wang GC, Zhang YL, Bian ZQ. Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of Methicillin-Resistant Staphylococcus aureus (MRSA). Molecules. 2012;17(9):10322–10330. doi:10.3390/molecules170910322
   PubMed Web of Science ®Google Scholar
• Xia S, Ma L, Wang G, et al. In vitro antimicrobial activity and the mechanism of berberine against methicillin-resistant Staphylococcus aureus isolated from bloodstream infection patients. IDR. 2002;15:1933–1944. doi:10.2147/IDR.S357077
   Google Scholar
• Liang RM, Yong XL, Duan YQ, et al. Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). World J Microbiol Biotechnol. 2014;30(11):2861–2869. doi:10.1007/s11274-014-1712-2
   PubMed Web of Science ®Google Scholar
• Wultańska D, Piotrowski M, Pituch H. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile. Eur J Clin Microbiol Infect Dis. 2020;39(7):1391–1399. doi:10.1007/s10096-020-03857-0
   PubMed Web of Science ®Google Scholar
• Menichini M, Lari N, Rindi L. Effect of efflux pump inhibitors on the susceptibility of Mycobacterium avium complex to clarithromycin. J Antibiot. 2020;73(2):128–132. doi:10.1038/s41429-019-0245-1
   PubMed Web of Science ®Google Scholar
• Tseng CY, Sun MF, Li TC, Lin CT. Effect of coptis chinensis on biofilm formation and antibiotic susceptibility in Mycobacterium abscessus. Evid Based Compl Alter Med. 2020;2020:1–9. doi:10.1155/2020/9754357
   Web of Science ®Google Scholar
• Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392–407. doi:10.1038/s41579-020-0331-1
   PubMed Web of Science ®Google Scholar
• Assefa M, Amare A, Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48(10):6987–6998. doi:10.1007/s11033-021-06690-6
   PubMed Web of Science ®Google Scholar
• Rai S, Kumar A, Darby EM, et al. Bacteriophage therapeutics to confront multidrug‐resistant Acinetobacter baumannii ‐ a global health menace. Environ Microbiol Rep. 2022;14(3):347–364. doi:10.1111/1758-2229.12988
   PubMed Web of Science ®Google Scholar
• Chen K, Wai Chi Chan E, Chen S. Evolution and transmission of a conjugative plasmid encoding both ciprofloxacin and ceftriaxone resistance in Salmonella. Emerg Micro Infect. 2019;8(1):396–403. doi:10.1080/22221751.2019.1585965
   PubMed Web of Science ®Google Scholar
• Chen K, Yang C, Dong N, et al. Evolution of ciprofloxacin resistance-encoding genetic elements in Salmonella. mSystems. 2020;5(6):e01234–20. doi:10.1128/mSystems.01234-20
   PubMed Web of Science ®Google Scholar
• Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–359. doi:10.1038/s41579-019-0315-1
   PubMed Web of Science ®Google Scholar
• Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018;4(1):18033. doi:10.1038/nrdp.2018.33
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019. Available from: https://stacks.cdc.gov/view/cdc/82532. Accessed October 19, 2023.
   Google Scholar
• Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. doi:10.1136/bmj.l4609
   PubMed Web of Science ®Google Scholar
• Gopalaswamy R, Shanmugam S, Mondal R, Subbian S. Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci. 2020;27(1):74. doi:10.1186/s12929-020-00667-6
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. doi:10.1183/13993003.00535-2020
   PubMed Web of Science ®Google Scholar
• Darby EM, Trampari E, Siasat P, et al. Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol. 2023;21(5):280–295. doi:10.1038/s41579-022-00820-y
   PubMed Web of Science ®Google Scholar
• Lamut A, Peterlin Mašič L, Kikelj D, Tomašič T. Efflux pump inhibitors of clinically relevant multidrug resistant bacteria. Med Res Rev. 2019;39(6):2460–2504. doi:10.1002/med.21591
   PubMed Web of Science ®Google Scholar
• Grande R, Puca V, Muraro R. Antibiotic resistance and bacterial biofilm. Expert Opin Ther Pat. 2020;30(12):897–900. doi:10.1080/13543776.2020.1830060
   PubMed Web of Science ®Google Scholar
• Liu D, Huang Q, Gu W, Zeng XA. A review of bacterial biofilm control by physical strategies. Crit Rev Food Sci Nutr. 2022;62(13):3453–3470. doi:10.1080/10408398.2020.1865872
   PubMed Web of Science ®Google Scholar
• Dutt Y, Dhiman R, Singh T, et al. The association between biofilm formation and antimicrobial resistance with possible ingenious bio-remedial approaches. Antibiotics. 2022;11(7):930. doi:10.3390/antibiotics11070930325
   Google Scholar
• Zhao Z, Guo M, Xu X, et al. In vitro synergistic inhibitory activity of natural alkaloid berberine combined with azithromycin against alginate production by Pseudomonas aeruginosa PAO1. Oxid Med Cell Longev. 2022;2022:1–10. doi:10.1155/2022/3858500
   Web of Science ®Google Scholar
• Mohammed YHE, Manukumar HM, Rakesh KP, Karthik CS, Mallu P, Qin HL. Vision for medicine: staphylococcus aureus biofilm war and unlocking key’s for anti-biofilm drug development. Microb Pathog. 2018;123:339–347. doi:10.1016/j.micpath.2018.07.002
   PubMed Web of Science ®Google Scholar
• Xu C, Wang F, Huang F, Yang M, He D, Deng L. Targeting effect of berberine on type I fimbriae of Salmonella Typhimurium and its effective inhibition of biofilm. Appl Microbiol Biotechnol. 2021;105(4):1563–1573. doi:10.1007/s00253-021-11116-1
   PubMed Web of Science ®Google Scholar
• Aswathanarayan JB, Vittal RR. Inhibition of biofilm formation and quorum sensing mediated phenotypes by berberine in Pseudomonas aeruginosa and Salmonella typhimurium. RSC Adv. 2018;8(63):36133–36141. doi:10.1039/C8RA06413J
   PubMed Web of Science ®Google Scholar
• Zhang C, Li Z, Pan Q, et al. Berberine at sub-inhibitory concentration inhibits biofilm dispersal in Staphylococcus aureus. Microbiology. 2022;168(9). doi:10.1099/mic.0.001243
   Web of Science ®Google Scholar
• Ning Y, Wang X, Chen P, et al. Targeted inhibition of methicillin-resistant Staphylococcus aureus biofilm formation by a graphene oxide-loaded aptamer/berberine bifunctional complex. Drug Deliv. 2022;29(1):1675–1683. doi:10.1080/10717544.2022.2079768
   PubMed Web of Science ®Google Scholar
• Zhao N, Isguven S, Evans R, Schaer TP, Hickok NJ. Berberine disrupts staphylococcal proton motive force to cause potent anti-staphylococcal effects in vitro. Biofilm. 2023;5:100117. doi:10.1016/j.bioflm.2023.100117
   PubMedGoogle Scholar
• Zhang X, Sun X, Wu J, et al. Berberine damages the cell surface of methicillin-resistant Staphylococcus aureus. Front Microbiol. 2008;11:621. doi:10.3389/fmicb.2020.00621
   Google Scholar
• Wang JJ, Wang J, Li Y, et al. A systematic Cochrane Review of antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Zhongguo Zhong Yao Za Zhi. 2021;46(1):33–40. doi:10.19540/j.cnki.cjcmm.20201002.601
   PubMedGoogle Scholar
• Ozturk M, Chia JE, Hazra R, et al. Evaluation of berberine as an adjunct to TB treatment. Front Immunol. 2021;12:656419. doi:10.3389/fimmu.2021.656419
   PubMed Web of Science ®Google Scholar
• Habtemariam S. Berberine pharmacology and the gut microbiota: a hidden therapeutic link. Pharmacol Res. 2020;155:104722. doi:10.1016/j.phrs.2020.104722
   PubMed Web of Science ®Google Scholar
• Lv Z, Peng G, Liu W, Xu H, Su J. Berberine blocks the relapse of Clostridium difficile Infection in C57BL/6 mice after standard vancomycin treatment. Antimicrob Agents Chemother. 2015;59(7):3726–3735. doi:10.1128/AAC.04794-14
   PubMed Web of Science ®Google Scholar